Analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to post $4.82 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Strongbridge Biopharma’s earnings. The highest sales estimate is $5.04 million and the lowest is $4.70 million. Strongbridge Biopharma reported sales of $4.30 million in the same quarter last year, which would suggest a positive year over year growth rate of 12.1%. The company is expected to announce its next quarterly earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Strongbridge Biopharma will report full-year sales of $20.06 million for the current year, with estimates ranging from $19.51 million to $20.96 million. For the next financial year, analysts anticipate that the business will post sales of $31.23 million, with estimates ranging from $23.17 million to $48.34 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Strongbridge Biopharma.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.09. The business had revenue of $4.34 million during the quarter, compared to analysts’ expectations of $4.69 million. Strongbridge Biopharma had a return on equity of 79.31% and a net margin of 227.79%.
A number of analysts have commented on the company. Oppenheimer restated a “buy” rating on shares of Strongbridge Biopharma in a research report on Tuesday, March 19th. BidaskClub upgraded Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 2nd. Zacks Investment Research upgraded Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Tuesday, March 19th. ValuEngine cut Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. Finally, TheStreet upgraded Strongbridge Biopharma from a “d-” rating to a “c-” rating in a research report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $13.14.
Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new stake in shares of Strongbridge Biopharma during the first quarter worth about $44,000. Stonebridge Capital Management Inc. purchased a new stake in shares of Strongbridge Biopharma during the first quarter worth about $55,000. Stifel Financial Corp purchased a new stake in shares of Strongbridge Biopharma during the fourth quarter worth about $73,000. ExodusPoint Capital Management LP purchased a new stake in shares of Strongbridge Biopharma during the first quarter worth about $167,000. Finally, BlueCrest Capital Management Ltd grew its position in shares of Strongbridge Biopharma by 41.5% during the first quarter. BlueCrest Capital Management Ltd now owns 40,240 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 11,805 shares in the last quarter. Hedge funds and other institutional investors own 49.11% of the company’s stock.
Shares of SBBP opened at $2.93 on Tuesday. The stock has a market capitalization of $164.14 million, a price-to-earnings ratio of 9.45 and a beta of 0.17. Strongbridge Biopharma has a 52 week low of $2.82 and a 52 week high of $7.76.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Further Reading: Overbought
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.